Posts

Where there is smoke …. there is fire – Congrats to co-first author Wael

Researchers discover how cigarette smoke impairs critical lung immune cells

Cigarette smoking is widespread and deadly, yet our understanding of how cigarette smoke actually causes serious respiratory illnesses in incomplete, which has severely hampered the development of effective treatments. In the Journal of Experimental Medicine (JEM) Australian researchers reveal how multiple chemicals found in cigarette smoke and e-cigarettes alter the function of a key type of immune cell found in the lungs.

The study suggests that these alterations make cigarette smokers, and those exposed to second- and third-hand smoke, more susceptible to respiratory infections, and exacerbate smoking-related inflammatory diseases such as chronic obstructive pulmonary disease (COPD).

Cigarette smoking is known to impair the immune system’s response to infections and promote inflammation in the lungs that can lead to or exacerbate COPD, the third leading cause of death worldwide. COPD patients are more susceptible to influenza infections that can, in turn, exacerbate the underlying disease by increasing airway inflammation and promoting the destruction of the lung’s air sacs. There are currently no effective treatments for COPD.

According to Dr Wael Awad, from Monash University’s Biomedicine Discovery Institute, until now the mechanisms underlying the skewed immune responses in people exposed to cigarette smoke, and how they are related to smoke-associated diseases like COPD remain unclear,” says Dr Awad, first author on the new JEM study.

Professor Jamie Rossjohn of Monash University’s Biomedicine Discovery Institute co-led the study with Professor David P. Fairlie of the Institute for Molecular Bioscience at University of Queensland, Professor Alexandra J. Corbett of the University of Melbourne, based at the Peter Doherty Institute for Infection and Immunity, and Professor Philip M. Hansbro of the Centenary Institute and University of Technology Sydney.

In their study, the researchers looked at the effects of cigarette smoke on Mucosal-Associated Invariant T (MAIT) cells, a type of immune cell found in the lungs and other tissues of the body. MAIT cells help fight off bacterial and viral infections and can promote inflammation or tissue repair.

MAIT cells are activated by a protein called MR1 that is found in almost every cell of the body. MR1 recognizes chemicals produced by bacteria and presents them at the surface of infected cells in order to activate MAIT cells and initiate an immune response. “We suspected that some of the more than 20,000 chemicals present in cigarette smoke that smokers inhale might also bind to MR1 and influence the activity of MAIT cells in the lungs”, Dr Awad said.

The researchers used computer modeling to predict which components of cigarette smoke might be recognized by MR1 and then found that several of these molecules not only bound to the protein but also either increased or decreased in amounts on the surface of cells. These chemicals, including benzaldehyde derivatives that are also used as flavorings in e-cigarettes, blocked activation of human MAIT cells by compounds produced by bacteria.

Unveiling the Molecular Impact of Smoking on Lung Health. This illustration explores how smoke components in cigarette and e-cigarette smoke obscures critical chemicals that bind MR1 and disrupt T cell functions in the lungs. Image: Erica Tandori

The research team then studied the effects of cigarette smoke on MAIT cells from human blood and mice and showed they reduced MAIT cell function. Mice repeatedly exposed to cigarette smoke developed symptoms of lung disease and this was worsened if also infected by influenza. Researchers found that long-term exposure to cigarette smoke altered the protection provided to mice by their MAIT cells, making them less able to fight off influenza infections and more prone to the development of COPD disease.

“We found that mice lacking MAIT cells were also protected from cigarette smoke-induced COPD, showing reduced levels of lung inflammation and no tissue deterioration in their lung’s air sacs” Profesor Hansbro said.  “This study demonstrates the power of collaboration and the insights we can gain with inter-disciplinary science,” Professor Corbett said.

“Overall, our study reveals that components of cigarette smoke can bind to the protein MR1 and reduce the functions of protective immune cells called MAIT cells. This increases susceptibility to infections worsens progression of lung disease” Awad says. The researchers now plan to investigate exactly which MAIT cell pathways are impacted by cigarette smoke, in order to learn how to better treat COPD and other lung diseases.

Read the full paper in Journal of Experimental Medicine: Cigarette smoke components modulate the MR1-MAIT axis. DOI: 10.1084/jem.20240896

Original article

Other related articles:

Monash study unravels another piece of the puzzle in how cancer cells may be targeted by the immune system

Effective immunity hinges on the ability to sense infection and cellular transformation. In humans, there is a specialised molecule on the surface of cells termed MR1. MR1 allows sensing of certain small molecule metabolites derived from cellular and microbial sources; however, the breadth of metabolite sensing is unclear.

Published in PNAS, researchers at the Monash University Biomedicine Discovery Institute (BDI) have identified a form of Vitamin B6 bound to MR1 as a means of engaging tumour-reactive immune cells. The work involved an international collaborative team co-led by researchers from the University of Melbourne.

 

Monash BDI authors on the study (L-R): Dr Patricia Illing, Dr Wael Awad, Dr Mitchell McInerney .

Monash BDI authors on the study (L-R): Dr Patricia Illing, Dr Wael Awad, Dr Mitchell McInerney .

According to Dr Illing, “Our findings suggest that Vitamin B6 molecules displayed by MR1 represent a means for the immune system to detect altered cellular metabolism/metabolite levels that may distinguish cancer cells,” she said.

“Identification of small molecules/metabolites able to activate immune cells with cancer reactivity is a key step in understanding how small molecule sensing might contribute to anti-cancer immunity.”

Central to this study were the unbiased mass spectrometry analysis of small molecules bound to MR1, the structural resolution of the interactions between MR1 and Vitamin B6, and immunological assays performed by lead authors Dr Mitchell McInerney and Dr Wael Awad at Monash Biomedicine Discovery Institute, and Dr Michael Souter and Mr Yang Kang at the University of Melbourne, Peter Doherty Institute.

While it’s not yet clear if the Vitamin B6 molecule can be utilised in therapeutics, “understanding the breadth of MR1 mediated immunity has the capacity to illuminate routes for therapeutic intervention,” Dr Illing said.

An important aspect of the finding is that MR1 differs very little across individuals – with few known genetic variants in the human population. “Thus, understanding immune activation mediated via MR1 may pave the way for therapeutic interventions with broad utility,” Dr Illing said.

She added that next steps for investigation will confirm whether Vitamin B6 and related molecules are displayed by the MR1 of cancer cells at altered levels to healthy body cells, thus enabling specific cancer targeting, or if other small molecules displayed by MR1 may help differentiate cancerous and healthy cells.

Read the full paper published in PNAS, titled MR1 presents vitamin B6–related compounds for recognition by MR1-reactive T cells
DOI: 10.1073/pnas.2414792121

Original article

Congrats to our newly appointed BDI Group Leaders: Wael, Jan and Adam

Monash BDI announce new Group Leaders

Monash Biomedicine Discovery Institute (BDI) is excited to announce 13 newly selected Group Leaders. These Group Leaders are part of a program created by Monash BDI to help early career researchers (ECRs) bridge the gap between senior postdoctoral fellow and independent lab head.

Professor Dena Lyras, Deputy Director at the Monash BDI, said that this program provides recognition and additional career momentum for researchers who are leading novel, cutting-edge research programs and developing their independence.

“Congratulations to all of the newly selected Group Leaders. This is a testament to the hard work and dedication of these researchers, and we look forward to seeing their next steps and achievements,” said Professor Lyras.

Congratulations to the newly selected Monash BDI Group Leaders:

Dr Wael Awad seeks to elucidate the mechanistic basis underpinning metabolite capture and loading of the MHC class I-related molecule “MR1” by cellular chaperones, by using cutting-edge molecular, immunological and biochemical approaches. He also explores the scope of environmental and microbial metabolites that can modulate human T cell immunity. Such studies pave the way for the development of innovative therapeutics based on selective modulation of T cell immunity.

Dr Jan Petersen’s research focuses on antimicrobial immunity and natural killer (NK) cell immunity. He investigates how T cells and NK cells recognise microbial peptide antigens presented by major histocompatibility complex (MHC) molecules, and aims to decipher the molecular mechanisms that define the ability of the adaptive immune system to distinguish between self and foreign. Focused on events central to infection and immunity, his work is aimed at understanding outcomes in various diseases and transplantation.

Dr Adam Shahine is focused on the molecular roles of lipids in the regulation and dysregulation of human adaptive immunity. Using structural biology, he seeks to investigate the mechanisms of lipid antigen recycling, and the presentation of lipid antigens by CD1 antigen presenting molecule family T cells.

Dr Deepak Adhikari aims to gain a better understanding of how mitochondria are formed and how they regulate the development of eggs and offspring.

Dr Asolina Braun aims to understand what initially causes psoriasis and hence to discover new treatments for this skin disease. Her research is focused on finding peptides that trigger and set off the detrimental immune response in psoriasis.

Dr Luke Formosa investigates how mitochondrial enzymes are built from their individual subunits, and how this process is disrupted in mitochondrial disease. One in 5,000 children will develop a mitochondrial disease, but about one-third of patients won’t have a genetic diagnosis. By discovering new genes that play a role in this process, the diagnosis of patients can be improved, paving the way for new treatments for this disease.

Dr Meiling Han’s research targets antibiotic resistance, focusing on the mechanism(s) underpinning the extensive membrane remodelling that occurs in Gram-negative bacteria and the interactions between remodelled bacterial membranes and membrane-targeting antimicrobials (e.g. lipopeptides). The fundamental mechanistic information that she generates will greatly inform the future design of much-needed antibiotics against antibiotic-resistant bacteria.

Dr Anja Knaupp’s research centres on characterising cell-type-specific sets of proteins and determining how they operate. Insight into these molecular mechanisms and drivers is key for our understanding of cellular identity and changes that, for example, occur during cancer development.

Dr Rachael Lappan aims to understand the nature and basis of microbial life in the atmosphere, the largest but most unexplored potential ecosystem on Earth. Using cutting-edge molecular and biogeochemical approaches, she aims to identify true microbial residents of the atmosphere, understand their mechanisms for survival in this environment and explore their role in seeding newly formed environments.

Dr Kate McArthur’s research uses a variety of microscopy and cell biology techniques to understand the mechanisms behind, and immune responses to, mitochondrial changes and aberrant cell death during disease.

Dr Nitin Patil is investigating peptide- and oligonucleotide-based antimicrobial drug development and delivery.

Dr Francesca Short combines genomic and molecular microbiology approaches to understand bacterial behaviour and adaptation. Her current research focuses on how bacteria control the production of virulence factors during infection and on how common disinfectants can compromise antibiotic efficacy.

Dr Yogitha Srikhanta investigates strategies that bacterial gut pathogens employ to proliferate, cause disease and survive, with a focus on antibiotic resistance and epigenetic-mediated gene regulation.

Original article

Congratulations Wael – Recipient of the ASBMB: 2022 EPPENDORF EDMAN ECR AWARD

THE 2022 EPPENDORF EDMAN ECR AWARD: WAEL AWAD

Monash Biomedical Discovery Institute

Monash University

Dr Wael Awad completed BSc and MSc studies at Cairo University, Egypt, resulting in two publications in the fields of molecular biophysics. With the support of an Erasmus Mundus Scholarship, Wael then moved to Sweden and completed a PhD under the supervision of Professor Derek Logan at Lund University. Wael’s PhD research was focused on the structural and functional characterisation of glycoproteins integral to cellular communication and signalling. His outstanding PhD dissertation led to five publications (four as first author and one review) and received the Best PhD Thesis Award from the MAX-IV Synchrotron (2015, Sweden). Wael then pursued his scientific career as a Research Fellow at Monash University (November 2015), under the mentorship of Professor Jamie Rossjohn. At Monash, he has brought a wealth of technical expertise in biochemistry and protein crystallography to markedly advance our understanding of the molecular correlates of metabolite-mediated T cell immunity.

Wael has demonstrated an ability to drive high-calibre research, and establish strong and fruitful collaborations as evidenced by his authorship of 19 original publications (nine as the first author and three reviews) in top-tier journals including Science, Nature Immunology, Science Immunology and Proceedings of the National Academy of Sciences USA. Of note, his seminal research on the molecular basis underpinning T cell recognition of microbial-derivatives was showcased on the cover of the April 2020 issue of Nature Immunology. This research paves the way for the development of innovative therapeutics based on selective modulation of T cell immunity. In addition, he has determined 28 protein crystal structures, the data for which have been deposited into the Protein Data Bank open access repository.

Wael has now established an international profile in the field of structural immunology as evidenced by his high impact publications and his selection to present at more than 30 national and international conferences. He has been recognised with more than 16 awards for research excellence including the prestigious International Union of Crystallography Young Scientist Award (New Zealand, 2018), the Robert Porter ECR Publication Prize 2021 for Laboratory-based Sciences (Monash University) and the Robin Anders Young Investigator Award 2021 (Lorne Proteins). He has recently been awarded an Australian ARC DECRA Fellowship (2022–2024) to support the development of his research program in the field of metabolite-mediated T cell immunity.

 

Original article